Sierra Oncology (SRRA) Given Media Impact Rating of 0.03

Share on StockTwits

Media coverage about Sierra Oncology (NASDAQ:SRRA) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sierra Oncology earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.7765045500986 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Sierra Oncology stock opened at $2.02 on Friday. The firm has a market capitalization of $152.07, a PE ratio of -2.40 and a beta of 2.38. Sierra Oncology has a 12 month low of $1.10 and a 12 month high of $4.09.

Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. During the same quarter last year, the firm earned ($0.30) earnings per share. analysts predict that Sierra Oncology will post -0.86 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. ValuEngine raised shares of Sierra Oncology from a “sell” rating to a “hold” rating in a report on Monday. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a report on Friday, March 2nd.

ILLEGAL ACTIVITY WARNING: This story was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://baseballnewssource.com/2018/04/06/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-sierra-oncology-srra-stock-price/2030079.html.

About Sierra Oncology

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.